The intervention strategy Signum Biosciences has developed involves the global modulation of signal transduction networks using a new class of therapeutic agents called Signal Transduction Modulators (STMs). Signaling networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Here at Signum, we have identified proprietary molecules that perturb the two most central of these global regulatory mechanisms: G-protein-mediated signaling and Protein phosphorylation.
Signum's G-Protein Modulators (GPMs) and Phospho-Protein Modulators (PPMs) have tremendous potential for treating severe regulatory dysfunctions that underlie inflammatory, CNS and severla other diseases. Signum is focused on developing our GPM technology initially in skin disease with a goal of delivering INDs for rosacea, atopic dermatitis, psoriasis and acne by 2012. Other applications of the GPM technology include asthma/COPD, IBD and many other inflammatory diseases. Signum is focused on developing our PPM in technology initially directed towards CNS diseases of neurodegeneration with a goal of delivering INDs for Alzheimer's Disease and Parkinson's Disease by 2012. Other applications of the PPM technology include metabolic diseases (e.g. diabetes).
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.